Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
In conclusion, dapagliflozin is an effective and generally well-tolerated treatment that represents a valuable new addition to the options available for symptomatic HFrEF.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Diabetes Mellitus | Endocrinology | Forxiga | Heart | Heart Failure | SGLT2 Inhibitors | Sodium